Novel Spliceosomal Defects in Myelodysplastic Syndromes

骨髓增生异常综合征中的新型剪接体缺陷

• 批准号: 9335972
• 负责人: Jaroslaw P Maciejewski
• 金额: $ 60.83万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9335972
• 关键词: 5' Splice Site; 5q31; Affect; Alleles; Alternative Splicing; Apoptosis; Biological Assay; CD34 gene; Cell Line; Cell model; Cells; Chromosome abnormality; Clinical; Clustered Regularly Interspaced Short Palindromic Repeats; Code; Data; Defect; Development; Differentiation and Growth; Disease; Dysmyelopoietic Syndromes; Engineering; Event; Evolution; Failure; Functional disorder; Gene Expression; Gene Proteins; Gene Targeting; Genes; Genomics; Goals; Hematopoiesis; Heterogeneity; Human; Human Engineering; In Vitro; Ineffective Hematopoiesis; Knock-in; Knock-out; Lesion; Link; Marrow; Mediating; Messenger RNA; Modeling; Molecular; Mus; Mutate; Mutation; Myeloproliferative disease; Oligonucleotides; Oncogenic; Outcome; Pathogenesis; Pathogenicity; Pathway interactions; Patients; Pattern; Phenocopy; Phenotype; Play; Protein Isoforms; Proteins; Publishing; RNA; RNA Binding; RNA Helicase; RNA Processing; RNA Splicing; Regulation; Role; SRSF2 gene; Sampling; Site; Somatic Mutation; Specificity; Spliced Genes; Spliceosomes; System; Technology; Testing; Tumor Suppressor Genes; Xenograft procedure; base; clinical phenotype; crosslinking and immunoprecipitation sequencing; cytopenia; experimental study; genetic analysis; improved; in vitro testing; in vivo; induced pluripotent stem cell; knock-down; leukemia; leukemogenesis; loss of function mutation; mRNA Expression; mutant; new therapeutic target; novel; overexpression; public health relevance; small hairpin RNA; transcriptome sequencing

 DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) are characterized by dysplastic ineffective hematopoiesis, cytopenias and leukemic evolution. New technological advances have allowed for improved analysis of genetic somatic defects. Among newly identified lesions, several spliceosomal factor genes were frequently found to be mutated. These included common mutations in SF3B1, ZRSR2, SRSF2 and U2AF1 as well as less prevalent mutations in PRPF8, DDX41 and others. This discovery has led to the hypothesis that alterations in the pattern of splicing of target genes plays a major role in the establishment or progression of MDS. This proposal focuses on our recent identification of inactivating mutations in the LUC7L2 gene and frequent haploinsufficiency due to deletions at 7q34 involving the LUC7L2 locus. Clinical analysis shows that deletion/low expression of LUC7L2 is associated with poor outcome. Recently published data show that LUC7L2 can reverse defective differentiation in del7q human iPS cells. Preliminary data shows that engineered human iPS cells with LUC7L2 haploinsufficiency have defective differentiation similar to del7q. LUC7L2 is thought to regulate 5' splice site choice during splicing. RNA-Seq results suggest that multiple genes have altered splicing patterns due to defects in LUC7L2. Our proposal is based on the hypothesis that mutations and/or haploinsufficiency of spliceosomal proteins such as LUC7L2 leads to specific types of missplicing of specific or distinct combinations of TSG and ultimately, that spliceosomal defects may phenocopy consequences of other molecular defects affecting specific genes or pathways. The goals of the proposal are to understand the consequences of LUC7L2 deficiency in relation to the development and progression of MDS. The effects of haploinsufficiency in primary cells and in engineered shRNA knockdown cells and LUC7L2 knock out iPS cells will be investigated in culture including effects on proliferation, differentiaion and apoptosis. We will perform splicing analysis using deep RNA sequencing to characterize splicing dysfunction and its consequences on mRNA expression to determine downstream mechanisms and target genes. To identify direct splicing targets, RNA splicing assays will be performed in vivo and in vitro with LUC7L2 knocked down and mutant knock-in cells. RNA CLIP-Seq and direct RNA binding analyses will be used to define the in vivo RNA substrates of LUC7L2 action. Finally, we will examine the roles of candidate downstream genes whose splicing and expression is altered in LUC7L2 defective cells and patient samples. Preliminary data suggests that LUC7L2 levels regulate the splicing of several downstream genes including SMAD5. Using engineered cell lines and/or patient samples, we will test the roles of the missplicing events by inducing or inhibiting alternative splice sites using antisense morpholino oligonucleotides. While in vitro testing will examine growth and differentiation, in vivo experiments will be carried out in NSG mouse xenografts containing knockdown, knock out or primary MDS cells haploinsufficient in LUC7L2.